Oncology Updates - Key Oncology News
- Oncofocus Team
- Jul 21
- 1 min read
July 2nd Week, 2026
Special Designation
⭐ PRG S&Tech Inc.’s Trineumin (small-molecule modulator of the abnormal TβR1-RKIP interaction (caused by NF2 gene mutation)) has been granted the Rare Pediatric Disease Designation (RPDD) by the US FDA for the Tx of Neurofibromatosis Type 2 (NF2) (Ref)
❓ What is the addressable market for NF2 in the US?
⭐ CSPC Pharmaceutical Group's SYS6043 (B7-H3 ADC) received the Breakthrough Therapy Designation from China’s NMPA for the Tx of platinum-resistant ovarian cancer, primary peritoneal carcinoma, and fallopian tube cancer as monotherapy (Ref)
❓ Which are some key ADC assets being developed for PROC and/or peritoneal cancer?
🔬 Pivotal China-specific Ph3 ARTEMIS-008 trial, of GSK and Jiangsu Hansoh Pharmaceutical Group Co., Ltd.’s risvutatug rezetecan (Ris-Rez; B7-H3 ADC) as a Tx of advanced or relapsed SCLC progressed on prior platinum-based chemo, has met the primary endpoint with the regimen demonstrating statistically significant and clinically meaningful improvements in OS compared with the SOC topotecan (Ref)
❓ How is Ris-Rez positioned in the SCLC developmental landscape?
Deals and Collaborations
🤝 Biocytogen and Whitehawk Therapeutics have entered into a global collaboration agreement to develop bispecific antibody-drug conjugates (BsADC); Whitehawk has an option to advance any resulting BsADC candidates as part of its pipeline and would hold global rights, while Biocytogen would be eligible for milestone payments and royalties (Ref)
❓ Which key companies are developing bispecific ADCs, and how many have entered the clinical pipeline?
To know answers to these questions and for additional insights, write to us at support@oncofocus.com.
🌐 References:
Comments